Dr. Reddy’s Laboratories Ltd. has launched a revolutionary solution for migraine management in Germany, marking its entry into digital therapeutics in Europe. The company’s non-invasive wearable device, Nerivio®, has been introduced through its subsidiary betapharm. This innovative device, approved by the United States Food and Drug Administration (USFDA) and CE-mark certified in Europe, offers a drug-free approach to managing migraine symptoms.
Nerivio® utilizes Remote Electrical Neuromodulation (REN) technology, providing acute and preventive treatment for migraine in adults and adolescents aged 12 years and above. With over 45,000 patients globally benefiting from the Nerivio® experience, backed by robust clinical evidence from more than 19,000 patients, it has emerged as a promising solution for migraine sufferers.
The launch in Germany follows Nerivio®’s successful introduction in India in 2023, where it became the first USFDA-approved REN device. In India, Nerivio® is supported by Dr. Reddy’s comprehensive patient support program called ‘M-Free’, aimed at providing holistic migraine care. The program includes services such as patient onboarding and counseling, device demonstrations, doorstep delivery, flexible payment options, informative content, and dedicated customer care.
Recognizing the global impact of migraine, Dr. Reddy’s is set to expand Nerivio®’s reach further. Following the launch in Germany, the device will be introduced in South Africa later this month, with subsequent launches planned in Spain and the UK. This expansion reflects the company’s commitment to addressing the significant burden of migraine worldwide.
Migraine is a prevalent health concern affecting millions of individuals globally, with a disproportionate impact on women. In Germany alone, approximately 8 to 10 million people suffer from migraine, with women being more affected than men. Similarly, in India, where around 213 million people experience migraine, women constitute approximately 60% of sufferers.
Dr. Reddy’s collaboration with Theranica, a prescribed digital therapeutics company, has been instrumental in bringing Nerivio® to multiple markets. Through this exclusive agreement, Nerivio® aims to provide effective migraine management solutions to a broader population, improving the quality of life for individuals living with this debilitating condition.
The introduction of Nerivio® in Europe aligns with ongoing efforts to enhance awareness and accessibility to innovative migraine treatments. The device’s approval by regulatory authorities in the US and Europe underscores its safety and efficacy in managing migraine symptoms. With migraine being a leading cause of disability worldwide, innovations like Nerivio® offer hope for improved outcomes and better quality of life for migraine sufferers.
As Nerivio® continues to gain momentum globally, Dr. Reddy’s remains committed to advancing migraine care through technology-driven solutions. By leveraging the latest advancements in digital therapeutics, the company aims to address the unmet needs of migraine patients and provide them with effective, convenient, and drug-free treatment options.
The launch of Nerivio® in Germany represents a significant milestone in Dr. Reddy’s journey towards transforming migraine management. With further expansion planned in key markets, Nerivio® has the potential to make a meaningful difference in the lives of millions affected by migraine worldwide.
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s said, “At a time when conversations on migraine focus on migraine[5] as a women’s health issue, relief from migraine through the use of technology and drug-free solutions, challenges associated with managing migraine during the child-bearing age, and distinguishing migraine from headache, we are happy to take our clinically-proven first digital therapeutics product, Nerivio®, to patients in our identified markets. Nerivio® has had an encouraging start in India, with recommendation from neurologists in India and bringing relief to patients living with migraine. We believe this product meets a genuine unmet clinical need among migraine patients, and has the potential to reduce pill burden in migraine. We look forward to receiving patient and HCP feedback from these markets.”
Overall, Dr. Reddy’s pioneering efforts in digital therapeutics underscore its commitment to innovation and improving patient outcomes in migraine management. Through collaborations, research, and continued investment in technology-driven solutions, the company aims to redefine the standard of care for migraine patients globally.